Aegis Therapeutics, LLC Awarded Patent for Monoclonal Antibody Formulations That Avoid Oxidative Damage Due to Polysorbate Surfactants
Published: Jul 24, 2012
SAN DIEGO, CA--(Marketwire - July 24, 2012) -
ProTek® excipients circumvent the problem of oxidative damage to biotherapeutics while achieving superior aggregation prevention -- keys to maintaining drug potency and reducing unwanted immunogenicity. ProTek® excipients also meet the FDA's Antimicrobial Effectiveness Test criteria without the need for an additional preservative when used in combination with another common GRAS excipient. Efforts to control the level of residual peroxides in polysorbate-containing solutions, including degassing and filling under nitrogen or inclusion of antioxidants, such as cysteine, glutathione or methionine, are often impractical and have been reported to result in interactions with the protein that cause further degradation or precipitation in some instances. Polysorbate damage to biotherapeutics is discussed at length in a just published review article in the Journal of Excipients and Food Chemicals: http://ojs.abo.fi/index.php/jefc/article/view/157/154.
Aegis will begin seeking additional licensees for the monoclonal antibody application of ProTek®. Other issued ProTek® related patents provide for non-invasive delivery and stabilization of all GLP-1 analogs; human growth hormone; parathyroid hormone and analogs; octreotide, and beta-, alpha-, and gamma-interferons, with others pending.
About Aegis Therapeutics
Aegis Therapeutics LLC is a drug delivery technology company commercializing its patented drug delivery and drug formulation technologies through product-specific licenses. Our Intravail® drug delivery technology enables the non-invasive delivery of a broad range of protein, peptide and non-peptide drugs that can currently only be administered by injection, via the oral, buccal, and intranasal administration routes, and with high bioavailability. Our ProTek® excipients stabilize, prevent aggregation, and reduce unwanted immunogenicity of protein and peptide therapeutics while avoiding the oxidative damage caused by polysorbate surfactants currently found in most protein injectable drugs.
For more information about Aegis, please visit: http://www.aegisthera.com.
Ed Maggio, PhD
Chief Executive Officer
Aegis Therapeutics LLC
1-858-618-1400 Ext. 101
Email: Email Contact